Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib (BRIDGET)

• ClinicalTrials.gov Identifier: NCT05323955
• Recruitment Status: Recruiting
• First Posted: April 12, 2022
• Last Update Posted: March 13, 2024
• Sponsor: Carey Anders, M.D.
• Collaborator: Seagen Inc.
• Information provided by (Responsible Party): Carey Anders, M.D., Duke University

Study Description

Brief Summary:

Patients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled. They will receive local therapy with stereotactic radiosurgery ± surgical resection if indicated followed by enrollment. Patients will continue standard of care trastuzumab/pertuzumab or T-DM1 with the addition of tucatinib. Hormone receptor positive patients requiring endocrine therapy should continue. Study treatment will continue until disease progression or intolerable side effects. Patients on trial with extracranial disease progression with stable intracranial disease should continue tucatinib into next line of therapy.

Condition or disease	Intervention/treatment	Phase
Brain Metastases; Human Epidermal Growth Factor 2 Positive Carcinoma of Breast; Advanced Breast Cancer	Drug: Trastuzumab; Drug: Trastuzumab Emtansine (T-DM1); Drug: Pertuzumab; Drug: Tucatinib	Phase 2

Detailed Description:

Patients with advanced HER2+ breast cancer on either (1) first-line trastuzumab/pertuzumab OR (2) second-line T-DM1 in the metastatic setting OR (3) adjuvant trastuzumab-based therapy or T-DM1 with isolated intracranial recurrence will be included. Patients with de novo metastatic disease and brain metastases or isolated intracranial recurrence can enter upon initiation of maintenance trastuzumab/pertuzumab after chemotherapy if deemed necessary by treating oncologist and meeting other inclusion criteria. Patients with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled. Third intracranial progression would be considered if > 12 month interval between second and third intracranial progression. They will receive local therapy with stereotactic radiosurgery ± surgical resection followed by enrollment. Patients will continue standard of care treatment trastuzumab/pertuzumab or T-DM1 with the addition of tucatinib. Hormone receptor-positive patients requiring endocrine therapy should continue.

Study treatment will continue until intercranial disease progression or intolerable side effects. Patients with extracranial disease progression while on trial with stable intracranial disease should continue tucatinib into the next line of therapy as described in protocol. If a subject continues tucatinib into the next line therapy they are still considered on study treatment and will be monitored according to the protocol. Cycles will continue consecutively and not restart. Once the subject comes off tucatinib they are considered off study treatment and will enter the follow up period.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 48 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
• Actual Study Start Date: March 23, 2023
• Estimated Primary Completion Date: April 2024
• Estimated Study Completion Date: April 2025

Arms and Interventions

Arm

Intervention/treatment

Experimental: Experimental Group; Trastuzumab/pertuzumab + tucatinib or T-DM1 + tucatinib 300mg of tucatinib taken orally twice a day. Taken on Days 1-21 of a 21 Day cycle (3 Weeks). Trastuzumab/Biosimilar administered per current package insert based on site standard of care guidelines Pertuzumab or Biosimilar administered per current package insert based on site standard of care guidelines Trastuzumab Emtansine (T-DM1) administered per current package insert based on site standard of care guidelines

Drug: Trastuzumab; Administer per current package insert based on site standard of care guidelines; Other Name: Herceptin; Drug: Trastuzumab Emtansine (T-DM1); Administer per current package insert based on site standard of care guidelines; Drug: Pertuzumab; Administer per current package insert based on site standard of care guidelines; Other Name: Perjeta; Drug: Tucatinib; 300 mg orally twice daily (21 Day Cycle); Other Name: Tukysa

Outcome Measures

Primary Outcome Measures :

1. Progression Free Survival (PFS) [ Time Frame: 3 years ]
   Evaluate the ability of tucatinib in combination with trastuzumab/pertuzumab or TDM-1 to prolong intracranial progression free survival (PFS) in patients compared to historical controls. PFS is defined as the time from the day of study treatment initiation until evidence of intracranial disease progression per RANO-BM or death from any cause.

Secondary Outcome Measures :

1. Progression Free Survival by RECIST 1.1 [ Time Frame: 3 years ]
   Evaluate the progression free survival by RECIST 1.1 criteria. PFS is defined as time from the day of study treatment initiation until evidence of disease progression per RECIST v1.1 or death from any cause.
2. Progression Free Survival of Extracranial Disease [ Time Frame: 3 years ]
   Evaluate PFS of extracranial disease. PFS is defined as time from the day of study treatment initiation until evidence of extracranial disease progression per RECIST v1.1 or death from any cause.
3. Distant Versus Local Intracranial Progression Free Survival [ Time Frame: 3 years ]
   Evaluate distant versus local intracranial PFS.
4. Site of First Progression [ Time Frame: 3 years ]
   Evaluate the site of first progression (CNS vs non-CNS). Site of first progression (CNS vs non-CNS) is defined by first site of progression on trial either within the central nervous system or extracranial disease as defined by investigator
5. Overall Survival (OS) [ Time Frame: 3 years ]
   Evaluate OS. OS defined as day of study treatment initiation until death from any cause.
6. Assess Adverse Events [ Time Frame: 2 months ]
   Evaluate the toxicity profile of agents in patients with brain metastases. Toxicity will be classified and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, version 5.0)

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Subject must meet all of the following applicable inclusion criteria to participate in this study:

• Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
• Age ≥ 18 years at the time of consent.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
• Locally advanced/unresectable or metastatic breast cancer with presence of brain metastases (Stage IV).
• Histologically confirmed HER2+ breast carcinoma by ASCO-CAP guidelines, with HER2+ defined by in situ hybridization (ISH), immunohistochemistry (IHC), or fluorescence in situ hybridization (FISH) methodology on most recent biopsy (primary tissue).
• Currently receiving: (1) first-line trastuzumab/pertuzumab with or without endocrine therapy OR (2) second-line T-DM1 in the metastatic setting OR (3) adjuvant trastuzumab-based therapy or T-DM1 with isolated intracranial recurrence. Patients with de novo metastatic disease and brain metastases or isolated intracranial recurrence can enter upon initiation of maintenance trastuzumab/pertuzumab after chemotherapy if chemotherapy deemed necessary by treating oncologist and meeting other inclusion criteria.
• Systemic disease otherwise stable per RECIST 1.1 or no evidence of extracranial disease.

• Adequate hepatic and renal function and hematologic parameters:

  • Absolute neutrophil count (ANC) ≥ 1.0 × 109/L
  • Platelets ≥ 100 × 109/L
  • Hemoglobin ≥ 9 g/dL
  • Total serum bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 2.5 × ULN (or ≤ 5 × ULN if liver metastases are present)
  • Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 50 mL/min as calculated using the Cockcroft-Gault (CG) equation
  • Left ventricular ejection fraction (LVEF) ≥ 50%.

• Central nervous system inclusion - Based on screening brain magnetic resonance imaging (MRI), patients must have ALL of the following:

  • Adequate local therapy to existing brain lesions ≥ 5mm including surgical resection and/or stereotactic radiosurgery
  • Limited to first or second intracranial progression. Third intracranial progression would be considered if > 12 month interval between second and third intracranial progression.
  • Time since stereotactic radiosurgery (SRS) is ≥ 7 days prior to first dose of study treatment.
  • Time since surgical resection is ≥ 14 days prior to first dose of study treatment.
  • Time since local therapy < 12 weeks. Patients with de novo metastastic breast cancer presenting with brain metastases may enter following cessation of chemotherapy if within 24 weeks of local therapy to the brain and brain metastases have remained stable based on brain MRI.

NOTE: Relevant records of any CNS treatment including radiation must be available to allow for classification of target and non-target lesions

• Females of childbearing potential must have a negative serum pregnancy test at screening. If a urine test is done and it is positive or cannot be confirmed as negative, a serum pregnancy test will be required. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months.
• Females of childbearing potential and males must be willing to abstain from heterosexual intercourse or to use contraception as outlined in the protocol.

Exclusion Criteria:

Subjects meeting any of the criteria below may not participate in the study:

• Previously been treated with: Lapatinib, neratinib, afatinib, tucatinib or other investigational HER2/epidermal growth factor receptor (EGFR) or HER2 tyrosine kinase inhibitor (TKI) at any time previously (patients treated with adjuvant neratinib allowed if relapse > 12 months after last dose).
• Clinically significant cardiopulmonary disease.

• Clinically significant acute infection requiring systemic antibacterial, antifungal, or antiviral therapy including:

  • tuberculosis (clinical evaluation that includes clinical history, physical examination, and radiographic findings, and TB testing in line with local practice),
  • hepatitis B (known positive HBV surface antigen (HBsAg) result),
  • hepatitis C, or
  • human immunodeficiency virus (positive HIV 1/2 antibodies)

NOTE: Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Subjects with HIV/AIDS with adequate antiviral therapy to control viral load would be allowed if they are stable and have been on treatment for ≥ 4 weeks prior to first dose of study drug(s). Subjects with viral hepatitis with controlled viral load would be allowed while on suppressive antiviral therapy. Testing not required.

• Unable for any reason to undergo MRI of the brain
• Use of a strong cytochrome P450 (CYP)2C8 inhibitor within 5 half-lives of the inhibitor, or a strong CYP3A4 or CYP2C8 inducer within 5 days prior to first dose of study treatment. See protocol.

• Central nervous system exclusion - Based on screening brain MRI, patients must not have any of the following:

  • Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a total daily dose of > 2 mg of dexamethasone (or equivalent)
  • Diffuse leptomeningeal disease or positive CSF cytology; however, discreet dural-based metastases are allowed
  • Poorly controlled seizures. Defined as seizures that continue to occur despite optimal anticonvulsant medications based on investigator discretion.
  • History of whole brain radiation therapy
  • Any untreated brain lesions ≥ 5 mm
• Active infection requiring intravenous systemic therapy.
• Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
• Patients with a prior or concurrent malignancy within last 3 years whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen, per treating physician discretion, are not eligible for this trial.
• Treatment with any investigational drug within 30 days prior to registration.

Contacts and Locations

Contacts

Contact: Carey Anders, MD; 919-684-5301; carey.anders@duke.edu

Contact: Rae Richards; 317-634-5842 ext 38; rrichards@hoosiercancer.org

Locations

United States, Massachusetts

Dana Farber Cancer Institute; Recruiting

Boston, Massachusetts, United States, 02215

Contact: Sarah Sammons, MD 919-668-5247 sarahl_sammons@dfci.harvard.edu

Contact: Hugh Meadows hughw_meadows@dfci.harvard.edu

United States, Michigan

University of Michigan Health System; Recruiting

Ann Arbor, Michigan, United States, 48109

Contact: Munira Hussain 734-936-8349 hussain@med.umich.edu

Principal Investigator: Aki Morikawa, MD

United States, Missouri

Washington University in St. Louis; Recruiting

Saint Louis, Missouri, United States, 63130

Contact: Samantha Ruzicka, LMSW 314-747-5209 ruzicka@wustl.edu

Principal Investigator: Nusayba Bagegni, MD

United States, North Carolina

Duke University Medical Center; Recruiting

Durham, North Carolina, United States, 27710

Contact: Carey Anders, MD 919-684-5301 dukebrain1@dm.duke.edu

Contact: Kelly Moulton 919-684-5301 dukebrain1@dm.duke.edu

United States, Ohio

Ohio State University Comprehensive Cancer Center; Recruiting

Columbus, Ohio, United States, 43210

Contact: Jean Koutou Essan, MPH 614-293-5637 JeanMartial.KoutouEssan@osumc.edu

Principal Investigator: Sasha Beyer, MD

United States, Oregon

Providence Portland Medical Center; Recruiting

Portland, Oregon, United States, 97213

Contact: Alison K Conlin, MD MPH 503-215-5696 alison.conlin@providence.org

Contact: Larisa Lundgren 503-215-0610 larisa.lundgren@providence.org

United States, Texas

MD Anderson Cancer Center; Recruiting

Houston, Texas, United States, 77030

Contact: Rashmi Murthy, MD MBE 713-563-8453 rmurthy1@mdanderson.org

Contact: Jill Swartz-Gomez, RN CCRP 713-792-2768 jschwartzgomez@mdanderson.org

Sponsors and Collaborators

Carey Anders, M.D.

Seagen Inc.

Investigators

• Principal Investigator: Carey Anders, MD; Duke Cancer Institute

More Information

• Responsible Party: Carey Anders, M.D., Sponsor Investigator, Duke University
• ClinicalTrials.gov Identifier: NCT05323955
• Other Study ID Numbers: Pro00109777
• First Posted: April 12, 2022
• Last Update Posted: March 13, 2024
• Last Verified: March 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Carey Anders, M.D., Duke University:

Brain metastases; HER2+ breast cancer; Trastuzumab; Pertuzumab; T-DM1

Additional relevant MeSH terms:

Breast Neoplasms; Neoplasm Metastasis; Brain Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Neoplastic Processes; Pathologic Processes; Central Nervous System Neoplasms; Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Trastuzumab; Pertuzumab; Ado-Trastuzumab Emtansine; Maytansine; Tucatinib; Antineoplastic Agents, Immunological; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Immunotoxins; Immunoconjugates; Immunologic Factors; Physiological Effects of Drugs